Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002652 · ClinicalTrials.gov registry record · Phase 2
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002652: Completed Phase 2 study, sponsored by University of Arkansas.
NCT00002652 is a Phase 2 study that has completed, run by University of Arkansas. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002652, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have refractory or relapsed multiple myeloma or Castleman's disease.
Interventions
- DRUG suramin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-05 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
What the finished NCT00002652 record still lists
NCT00002652 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which suramin is the first listed.
NCT00002652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002652 about?
NCT00002652 is a clinical study titled "Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have refractory or relapsed multiple myeloma or Castleman's disease.
What is the current status of trial NCT00002652?
This trial is currently completed. It is a Phase 2 study. The study started on 1995-05. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00002652?
The interventions under investigation include: suramin (DRUG).
Who is sponsoring clinical trial NCT00002652?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia